Suchergebnisse
10
Alles
United States FDA Approves NM8074 (Ruxoprubart) IND for Treating Dermatomyositis (DM): A Chronic Inflammatory Disorder of the Skin
24. Februar 2025 10:11 ET
|
NovelMed Therapeutics Inc
--- The United States FDA Approves the Initiation for Phase II Efficacy Trial in Dermatomyositis (DM) Patients: A Skin & Muscle Disorder DM is an immune-mediated myopathy characterized by...
Conduit Progresses Phase II of its AI Initiative with Sarborg
20. Februar 2025 08:00 ET
|
Conduit Pharmaceuticals
Conduit Progresses Phase II of its AI Initiative with Sarborg
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
13. Februar 2025 08:00 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of Tiprelestat
08. Januar 2025 04:00 ET
|
AKAMPION
- tiakis and Stanford University are preparing for a Phase II in Pulmonary Arterial Hypertension (PAH) Kiel, Germany, January 8, 2025 – tiakis Biotech AG, a clinical-stage biopharmaceutical company...
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
21. November 2024 07:30 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
12. August 2024 07:00 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
08. August 2024 06:30 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
26. Februar 2024 02:05 ET
|
Boehringer Ingelheim
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of...
MetrioPharm veröffentlicht Studiendaten, die die Wirkung einer Host-Directed Therapy in COVID-19 zeigen
31. Januar 2024 05:00 ET
|
AKAMPION
Ergebnisse stammen aus der klinischen Studie CT-05 an 131 hospitalisierten Patienten mit COVID-19Die Daten zeigen, dass MetrioPharms Leitsubstanz MP1032 eine mit Remdesivir vergleichbare Wirksamkeit...
MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
31. Januar 2024 05:00 ET
|
AKAMPION
Results of clinical trial CT-05 in 131 hospitalized patients with COVID-19Trial data demonstrate that MetrioPharm´s lead compound MP1032 has comparable efficacy to remdesivir with several additional...